SCHEMBL756224

SCHEMBL756224

C=CC(=O)OCC[N+](C)(C)CC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 8/20 0.55
HPGD P15428 1/20 0.55
ALDH1A1 P00352 4/20 0.50
TP53 P04637 3/20 0.50
HIF1A Q16665 3/20 0.50
CYP3A4 P08684 2/20 0.50
HSD17B10 Q99714 1/20 0.50
THRB P10828 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.37
MAPK1 P28482 1/20 0.37
BBOX1 O75936 1/20 0.37
CHRM5 P08912 3/20 0.36
CHRM1 P11229 3/20 0.36
CHRM3 P20309 3/20 0.36
CHRM2 P08172 2/20 0.36
CHRM4 P08173 2/20 0.36
HTR1A P08908 2/20 0.36
CHRNB2 P17787 2/20 0.36
CHRNA7 P36544 2/20 0.36
CHRNA4 P43681 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL27992105 0.98 TSHR (0.53) TSHRHPGDALDH1A1TP53HIF1A
Hydrochloric Acid SCHEMBL2019272 0.98 TSHR (0.53) TSHRHPGDALDH1A1TP53HIF1A
Bromide SCHEMBL9403200 0.98 TSHR (0.53) TSHRHPGDALDH1A1TP53HIF1A
Hydrochloric Acid SCHEMBL31147007 0.96 TSHR (0.52) TSHRHPGDALDH1A1TP53HIF1A
Sulfuric Acid SCHEMBL28894455 0.93 TSHR (0.49) TSHRHPGDALDH1A1TP53HIF1A
Sulfuric Acid SCHEMBL7901326 0.92 TSHR (0.47) TSHRHPGDALDH1A1TP53HIF1A
Acrylamide SCHEMBL28031980 0.92 TSHR (0.47) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL13791296 0.90 TSHR (0.63) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL3760076 0.89 TSHR (0.61) TSHRHPGDALDH1A1TP53HIF1A
Sulfuric Acid Dimethyl Ester SCHEMBL30819480 0.89 TSHR (0.45) TSHRHPGDALDH1A1TP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085828-A1 SYSTEM AND METHOD FOR CONTROLLED POLYMER DEPOLYMERIZATION Intropic Materials Corporation (US) 2025-04-24 WO claimed
US-20250129391-A1 SYSTEM AND METHOD FOR CONTROLLED POLYMER DEPOLYMERIZATION Intropic Materials Corporation (US) 2025-04-24 US claimed
CN-104797363-A Method for making silver nanostructures and copolymers useful in such method RHODIA OPERATIONS 2015-07-22 CN claimed
US-20080031846-A1 Compositions with enhanced antimicrobial efficacy against acanthamoebae BORAZJANI ROYA 2008-02-07 US claimed
EP-1852133-A2 Compositions with enhanced antimicrobial efficacy against acanthamoebae BAUSCH & LOMB INCORPORATED (US) 2007-11-07 EP claimed
EP-0920487-B1 COMPOSITION AND METHOD FOR INHIBITING THE DEPOSITION OF PROTEIN ON CONTACT LENS BAUSCH & LOMB (US) 2003-04-09 EP claimed
US-6096138-A IMMERSION IN AQUEOUS SOLUTION OF POLYQUATERNARY AMMONIUM SALT CATIONIC POLYMER BAUSCH & LOMB INCORPORATED (US) 2000-08-01 US claimed
US-20250355378-A1 TONER AND METHOD OF MANUFACTURING TONER KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2025-11-20 US disclosed
WO-2025085828-A1 SYSTEM AND METHOD FOR CONTROLLED POLYMER DEPOLYMERIZATION Intropic Materials Corporation (US) 2025-04-24 WO disclosed
US-20250129391-A1 SYSTEM AND METHOD FOR CONTROLLED POLYMER DEPOLYMERIZATION Intropic Materials Corporation (US) 2025-04-24 US disclosed
WO-2024203883-A1 OPHTHALMIC MEDICAL INSTRUMENT AND MANUFACTURING METHOD THEREFOR 三菱ケミカル株式会社 2024-10-03 WO disclosed
US-20240218291-A1 CONTACT LENS TREATING SOLUTION JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-07-04 US disclosed
WO-2024132271-A1 CONTACT LENS TREATING SOLUTION BAUSCH + LOMB IRELAND LIMITED (IE) 2024-06-27 WO disclosed
EP-1279697-A1 POROUS RESIN FILM Yupo Corporation (JP) 2003-01-29 EP disclosed
US-20020009732-A1 Version with markings to show changes made ORTHO-CLINICAL DIAGNOSTICS, INC. 2002-01-24 US disclosed
US-6323165-B1 AQUEOUS SOLUTION COMPRISING EFFECTIVE AMOUNT OF AT LEAST ONE POLYQUATERNIUM POLYMER HAVING SPECIFIED WEIGHT AVERAGE MOLECULAR WEIGHT, COMPRISING ABOUT 10 TO 45 MOLE PERCENT OF NET QUATERNARY-AMINE-FUNCTIONAL REPEAT UNITS BAUSCH & LOMB INCORPORATED 2001-11-27 US disclosed
EP-1130398-A2 Analytical elements Ortho-Clinical Diagnostics, Inc. (US) 2001-09-05 EP disclosed
US-6096138-A IMMERSION IN AQUEOUS SOLUTION OF POLYQUATERNARY AMMONIUM SALT CATIONIC POLYMER BAUSCH & LOMB INCORPORATED (US) 2000-08-01 US disclosed
EP-0920487-A1 COMPOSITION AND METHOD FOR INHIBITING THE DEPOSITION OF PROTEIN ON CONTACT LENS BAUSCH & LOMB INCORPORATED (US) 1999-06-09 EP disclosed
WO-1997043373-A1 COMPOSITION AND METHOD FOR INHIBITING THE DEPOSITION OF PROTEIN ON CONTACT LENS BAUSCH & LOMB INCORPORATED (US) 1997-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080031846-A1 Compositions with enhanced antimicrobial efficacy against acanthamoebae LAGE3, PKD2, CUTA TSHR 4655/4885HPGD 4729/4885ALDH1A1 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.